Baxter International | BAX - Operating Profit


Baxter International reported $314M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Abbott USD 1.36B 775M Sep/2026
AngioDynamics USD -2.51M 5.41M Sep/2025
Artivion USD 4.79M 6.85M Dec/2025
AtriCure USD 4.35M 5.31M Sep/2026
Baxter International USD 314M 38M Sep/2026
Becton, Dickinson and Co. USD 1.11B 357M Sep/2026
Boston Scientific USD 1.01B 232M Sep/2026
Cooper Companies USD 222M 253M Jun/2026
Dexcom USD 318.3M 63M Jun/2026
Edwards Lifesciences USD 542.7M 23.2M Sep/2026
Fresenius EUR 639M 80M Sep/2026
Globus Medical USD 178.23M 224.2M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
ICU Medical USD 58.59M 1.84M Sep/2026
Inogen USD -7.79M 728K Sep/2024
Insulet USD 189.8M 60.1M Sep/2026
Integra LifeSciences USD 42.65M 1.36M Sep/2026
Intuitive Surgical USD 1.05B 69.9M Sep/2026
J&J USD 6.47B 1B Sep/2026
Laboratory Of America USD 418M 38.7M Sep/2026
Medtronic USD 1.84B 254M Jun/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Quest Diagnostics USD 479M 20M Sep/2026
Smith & Nephew USD 505M 65M Jun/2026
Stryker USD 1.79B 687M Jun/2026
Tandem Diabetes Care USD -2.37M 11.42M Sep/2026
Teleflex USD -105.77M 178.84M Sep/2026
Terumo JPY -18.68B 108.16B Sep/2026
Zimmer Biomet Holdings USD 341.5M 3.2M Sep/2026